BACKGROUND: Growing evidence suggests that @entity1200 may be involved in the physiopathology of @entity162 , with typical first-line treatment using @entity1091 and @entity1089 serving to restore pro- @entity32 status. This study aimed to explore the relationship between inflammatory cytokines-especially regulatory factors and the effect of combination treatment-with @entity1089 and @entity1091 in @entity162 @entity1 . METHODS: 41 @entity1 of @entity162 with @entity162 episode were enrolled and received combination treatment with @entity1089 and @entity1091 . Blood sampling and assessments were performed at baseline and after 8-week treatment. YMRS was used to evaluate the severity of @entity162 at the same time of detecting plasma levels. A control group comprised of 36 age and gender matched healthy volunteers were enrolled, and their blood samples were assessed at the time of enrollment. RESULTS: @entity2533 and @entity4452 plasma levels in @entity1 were significantly higher than healthy controls at baseline (P<0.05). When comparing remitted @entity1 with non-remitted @entity1 , initial plasma level @entity2533 was higher (P=0.029) while @entity4452 was lower (P=0.035). The plasma levels of @entity310 , @entity2533 , @entity4452 and @entity4155 significantly decreased after treatment among the @entity1 who achieved response (P<0.05). LIMITATIONS: The relatively small sample size in @entity1 and control groups should be considered as a limitation of the study. CONCLUSIONS: The high initial plasma level of @entity2533 and low initial plasma level of @entity4452 indicated better prognosis during combination treatment with @entity1089 and @entity1091 in @entity162 @entity1 . The trend of decreasing plasma levels of @entity310 , @entity2533 , @entity4452 and @entity4155 indicated therapeutic effect.

@entity4452 and @entity2533 levels as potential predictive biomarkers in treatment of @entity162 with acute XXXX episode.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity162 :: ('MESH:D001714', 'Disease') :: ['manic', 'bipolar I disorder', 'manic symptoms', 'bipolar disorders'] @entity310 :: ('7124', 'Gene') :: ['TNF-a'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['immune dysfunction'] @entity2533 :: ('7040', 'Gene') :: ['TGF-b1'] @entity4155 :: ('3605', 'Gene') :: ['IL-17'] @entity1091 :: ('MESH:D008094', 'Chemical') :: ['lithium'] @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine'] @entity4452 :: ('51561', 'Gene') :: ['IL-23']
@entity162 :: (MESH:D001714,Disease) :: ['manic']
